IART - CIK 0000917520
The table below shows INTEGRA LIFESCIENCES HOLDINGS CORP's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $50.38M | $129.38M | $139.96M | $264.47M | $312.43M | $203.83M |
| Capital expenditure | $81.44M | $104.42M | $66.86M | $42.34M | $48.02M | $38.89M |
| Investing cash flow | -$108.06M | -$390.81M | -$94.18M | -$58.58M | -$161.44M | -$68.07M |
| Dividends paid | - | - | - | - | - |
INTEGRA LIFESCIENCES HOLDINGS CORP reported operating cash flow of $50.38M for fiscal year 2025. That is down 61.1% from $129.38M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $116.41M (FY 2016) to $50.38M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $221.00K | $52.47M | $275.00M | $125.00M | $0.00 | $100.00M |
| Financing cash flow | $28.34M | $237.86M | -$229.93M | -$251.95M | -$98.23M | $121.63M |